PBD Biotech specializes in phage-based diagnostics, utilizing proprietary technology to detect mycobacteria in blood samples for the early identification of tuberculosis. Their Actiphage test provides a reliable method for screening active TB infections, enhancing disease management in both humans and animals.
Funding
$2.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MEFounders
Product
Problem
Current methods for detecting tuberculosis (TB) often lack the sensitivity for early identification, hindering timely intervention and disease management. Traditional TB diagnostic approaches can be slow, resource-intensive, and may not effectively detect active infections, especially in early stages.
Solution
PBD Biotech offers Actiphage, a phage-based diagnostic test designed for the rapid and sensitive detection of live mycobacteria in blood samples, enabling early identification of active TB infections. The proprietary technology utilizes bacteriophages to identify the presence of mycobacteria, the causative agent of TB, providing a more reliable screening method compared to traditional techniques. Actiphage aims to improve TB disease management by offering a faster and more accurate method for detecting active infections in both humans and animals. The test has been awarded a US Patent grant for diagnostic kit.
Target Audience
The primary target audience includes healthcare providers, veterinarians, and researchers involved in the diagnosis and management of tuberculosis in humans and animals.
Features
- Utilizes a novel phage-based assay for detecting mycobacteria in blood samples.
- Designed for early detection of active TB infections.
- Applicable for both human and animal TB screening.
- Aims to provide rapid results compared to traditional TB detection methods.
- Proprietary, patented technology.